Divesiran: Presented at ASCO 2024, the SANRECO trial is an ongoing phase 1/2 study evaluating divesiran, a novel GalNAc-conjugated siRNA targeting TMPRSS6 (transmembrane protease, serine 6), in patients with PV. This evidence concerns the gene TMPRSS6 and acquired polycythemia vera.